Hormonal therapies available include tamoxifen, which despite a lack of MBC efficacy data, is the adjuvant treatment of choice and is recommended for hormone-receptor positive tumours for a minimum of 5 years [6,63,64]. The gene discussed is NR4A1; the disease is neoplasm.